Bone changes in early rheumatoid arthritis

Michael J. Green, Atulya (Atul) Deodhar

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Bone disease in rheumatoid arthritis affects the peri-articular and axial skeleton and is a major cause of disability. Recent studies have shown that pro-inflammatory cytokines stimulate the expression of osteoprotegerin ligand, a transmembrane protein of the tumour necrosis factor ligand superfamily, on synoviocytes and activated T cells. Osteoprotegerin ligand stimulates osteoclast formation and activation, membrane-bound and soluble osteoprotegerin ligand leading to osteoporosis as well as erosions. Bone densitometry using dual energy X-ray absorptiometry is an objective and precise method for monitoring this bone disease. Bone loss is more rapid in patients with early rheumatoid arthritis and correlates well with measures of inflammation and function. Data are emerging that monitoring bone loss of the hands in early rheumatoid arthritis could be an outcome measure and a prognostic indicator of future functional disability. Suppressing inflammation effectively and the use of bone active agents can reduce the rate of loss. In animal models, osteoprotegerin - a decoy receptor of osteoprotegerin ligand - blocks osteoporosis and erosions without affecting inflammation. The use of new biological agents could in future effectively prevent and treat rheumatoid bone disease.

Original languageEnglish (US)
Pages (from-to)105-123
Number of pages19
JournalBest Practice and Research: Clinical Rheumatology
Volume15
Issue number1
DOIs
StatePublished - 2001

Fingerprint

RANK Ligand
Bone Diseases
Rheumatoid Arthritis
Bone and Bones
Inflammation
Osteoporosis
Tumor Necrosis Factors
Hand Bones
Osteoprotegerin
Densitometry
Photon Absorptiometry
Biological Factors
Osteoclasts
Skeleton
Animal Models
Joints
Outcome Assessment (Health Care)
Cytokines
T-Lymphocytes
Membranes

Keywords

  • Hand bone densitometry
  • Osteoporosis
  • Osteoprotegerin
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Rheumatology

Cite this

Bone changes in early rheumatoid arthritis. / Green, Michael J.; Deodhar, Atulya (Atul).

In: Best Practice and Research: Clinical Rheumatology, Vol. 15, No. 1, 2001, p. 105-123.

Research output: Contribution to journalArticle

@article{c49d353b1ff9460490b2688c1cd8607f,
title = "Bone changes in early rheumatoid arthritis",
abstract = "Bone disease in rheumatoid arthritis affects the peri-articular and axial skeleton and is a major cause of disability. Recent studies have shown that pro-inflammatory cytokines stimulate the expression of osteoprotegerin ligand, a transmembrane protein of the tumour necrosis factor ligand superfamily, on synoviocytes and activated T cells. Osteoprotegerin ligand stimulates osteoclast formation and activation, membrane-bound and soluble osteoprotegerin ligand leading to osteoporosis as well as erosions. Bone densitometry using dual energy X-ray absorptiometry is an objective and precise method for monitoring this bone disease. Bone loss is more rapid in patients with early rheumatoid arthritis and correlates well with measures of inflammation and function. Data are emerging that monitoring bone loss of the hands in early rheumatoid arthritis could be an outcome measure and a prognostic indicator of future functional disability. Suppressing inflammation effectively and the use of bone active agents can reduce the rate of loss. In animal models, osteoprotegerin - a decoy receptor of osteoprotegerin ligand - blocks osteoporosis and erosions without affecting inflammation. The use of new biological agents could in future effectively prevent and treat rheumatoid bone disease.",
keywords = "Hand bone densitometry, Osteoporosis, Osteoprotegerin, Rheumatoid arthritis",
author = "Green, {Michael J.} and Deodhar, {Atulya (Atul)}",
year = "2001",
doi = "10.1053/berh.2000.0129",
language = "English (US)",
volume = "15",
pages = "105--123",
journal = "Best Practice and Research in Clinical Rheumatology",
issn = "1521-6942",
publisher = "Bailliere Tindall Ltd",
number = "1",

}

TY - JOUR

T1 - Bone changes in early rheumatoid arthritis

AU - Green, Michael J.

AU - Deodhar, Atulya (Atul)

PY - 2001

Y1 - 2001

N2 - Bone disease in rheumatoid arthritis affects the peri-articular and axial skeleton and is a major cause of disability. Recent studies have shown that pro-inflammatory cytokines stimulate the expression of osteoprotegerin ligand, a transmembrane protein of the tumour necrosis factor ligand superfamily, on synoviocytes and activated T cells. Osteoprotegerin ligand stimulates osteoclast formation and activation, membrane-bound and soluble osteoprotegerin ligand leading to osteoporosis as well as erosions. Bone densitometry using dual energy X-ray absorptiometry is an objective and precise method for monitoring this bone disease. Bone loss is more rapid in patients with early rheumatoid arthritis and correlates well with measures of inflammation and function. Data are emerging that monitoring bone loss of the hands in early rheumatoid arthritis could be an outcome measure and a prognostic indicator of future functional disability. Suppressing inflammation effectively and the use of bone active agents can reduce the rate of loss. In animal models, osteoprotegerin - a decoy receptor of osteoprotegerin ligand - blocks osteoporosis and erosions without affecting inflammation. The use of new biological agents could in future effectively prevent and treat rheumatoid bone disease.

AB - Bone disease in rheumatoid arthritis affects the peri-articular and axial skeleton and is a major cause of disability. Recent studies have shown that pro-inflammatory cytokines stimulate the expression of osteoprotegerin ligand, a transmembrane protein of the tumour necrosis factor ligand superfamily, on synoviocytes and activated T cells. Osteoprotegerin ligand stimulates osteoclast formation and activation, membrane-bound and soluble osteoprotegerin ligand leading to osteoporosis as well as erosions. Bone densitometry using dual energy X-ray absorptiometry is an objective and precise method for monitoring this bone disease. Bone loss is more rapid in patients with early rheumatoid arthritis and correlates well with measures of inflammation and function. Data are emerging that monitoring bone loss of the hands in early rheumatoid arthritis could be an outcome measure and a prognostic indicator of future functional disability. Suppressing inflammation effectively and the use of bone active agents can reduce the rate of loss. In animal models, osteoprotegerin - a decoy receptor of osteoprotegerin ligand - blocks osteoporosis and erosions without affecting inflammation. The use of new biological agents could in future effectively prevent and treat rheumatoid bone disease.

KW - Hand bone densitometry

KW - Osteoporosis

KW - Osteoprotegerin

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=0035041256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035041256&partnerID=8YFLogxK

U2 - 10.1053/berh.2000.0129

DO - 10.1053/berh.2000.0129

M3 - Article

VL - 15

SP - 105

EP - 123

JO - Best Practice and Research in Clinical Rheumatology

JF - Best Practice and Research in Clinical Rheumatology

SN - 1521-6942

IS - 1

ER -